Compounds > 6-bromo-2-naphthol
Page last updated: 2024-11-05

6-bromo-2-naphthol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-Bromo-2-naphthol is a brominated derivative of 2-naphthol. It is a solid, crystalline compound that is typically used as a reagent in organic synthesis, particularly in the preparation of other organic compounds. It has been used in the synthesis of various dye intermediates and pharmaceuticals. It is also used as a starting material for the synthesis of other brominated naphthol derivatives. The compound is typically synthesized through the bromination of 2-naphthol using bromine in acetic acid. The bromination reaction is highly regiospecific, meaning that the bromine atom selectively attaches to the 6-position of the naphthol molecule. 6-Bromo-2-naphthol is a useful building block for the synthesis of a variety of organic compounds and its chemistry is of interest to researchers in the fields of organic synthesis, pharmaceuticals, and materials science.'
```

6-bromo-2-naphthol: RN given refers to cpd with specified bromide locant [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

6-bromo-2-naphthol : A member of the class of naphthols that is 2-naphthol carrying an additional bromo substituent at position 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID27144
CHEBI ID34466
SCHEMBL ID49667
MeSH IDM0106699

Synonyms (63)

Synonym
BIDD:ER0052
AC-12234
BB 0220620
bromo-6 naphtol-2 [french]
einecs 239-279-0
ai3-18464
2-naphthol, 6-bromo-
nsc 17563
2-naphthalenol, 6-bromo-
nsc17563
15231-91-1
nsc-17563
6-bromo-.beta.-naphthol
inchi=1/c10h7bro/c11-9-3-1-8-6-10(12)4-2-7(8)5-9/h1-6,12
6-bromo-2-naphthol
6-bromo-2-naphthol, 97%
B0621
HMS1651O22
6-bromonaphthalen-2-ol
AKOS000120485
6-bromo-naphthalen-2-ol
bromo-6 naphtol-2
87f10ahz3o ,
unii-87f10ahz3o
FT-0601033
AM20060520
F0701-0028
6-bromo2-hydroxynaphthalene
SCHEMBL49667
B-8922
2-hydroxy-6-bromonaphthalene
6-hydroxy-2-bromonaphthalene
2-bromo-6-hydroxynaphthalene
6-bromo-2-naphthalinol
6-bromo-beta-naphthol
CHEBI:34466
TS-00535
2-bromo-6-hydroxy-naphthalene
2-bromo-6-naphthol
6-bromo2-naphthol
6-bromo-2-napthol
6-bromo-naphthalene-2-ol
6-bromonaphth-2-ol
6-bromonapthalen-2-ol
6-bromo-2-hydroxynaphthalene
6-bromonaphthalene-2-ol
6bromo-2-naphthol
6-bromo-2-naphthalenol
6-bromo- 2hydroxynaphthalene
2-hydroxy-6-bromo-naphthalene
6-bromo-2-naphtol
W-201358
STR02406
mfcd00004081
DTXSID5074551
STL451630
CS-W001952
SY006200
(e)-hydrazinecarbohydrazonamide hydrochloride
Q27116088
EN300-17905
A851722
Z57074412
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
naphtholsAny hydroxynaphthalene derivative that has a single hydroxy substituent.
organobromine compoundA compound containing at least one carbon-bromine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's4 (44.44)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.94 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2-naphthol
2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.		2.9240naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		1.9610D-glucopyranoseepitope;
mouse metabolite
fast blue b
Fast Blue B: reagent for marijuana detection; RN given refers to parent cpd. fast blue salt B : An organic chloride salt composed of 3,3'-dimethoxy[1,1'-biphenyl]-4,4'-bis(diazonium), zinc and chloride ions in a ratio of 1:1:4. Used for detection of marijuana metabolites in urine.. fast blue B : The aromatic diazonium ion formed from diazotisation of 3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diamine.		1.9610aromatic diazonium ionhistological dye
glycosides
[no description available]		1.9610
sodium dodecyl sulfate
Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.		7.0110organic sodium saltdetergent;
protein denaturant
acebutolol
alpha-D-glucosyl-(1->4)-alpha-D-mannose : An alpha-D-glucosyl-(1->4)-D-mannopyranose in which the anomeric hydroxy group has alpha configuration.		1.9610alpha-D-glucosyl-(1->4)-D-mannopyranose
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
Acinetobacter Infections
Infections with bacteria of the genus ACINETOBACTER.		02.4110